CEL-SCI Corporation news

   Watch this stock
Showing stories 1 - 10 of about 88   

Articles published

CVM 1.85 -0.01 (-0.54%)
price chart
CEL-SCI Reaches Full Enrollment in Pivotal Phase 3 Head and Neck Cancer Study
Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving ...
Analyst's Hold rated Stock: CEL-SCI Corporation (CVM)  Street Observer (press release)
Cel Sci Corporation (NYSEAMERICAN:CVM) Has Decline in Shorts  BZ Weekly
Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?
I've gone through fur or five significant redrafts of this article since I started trying to get it organized at the end of August, and each time I thought I had captured a good representation of the current situation for Cel-Sci Corp. (NYSEMKT:CVM ...
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring ...
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine ...
CEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head ...  StreetInsider.com
A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
Cel-Sci Corporation (NYSEMKT:CVM) is on the verge of several significant milestones and inflection points during the first several months of 2016.
CEL-SCI Corp.
CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study. CEL-SCI reports recent data review by the IDMC for its pivotal Phase 3 head and neck cancer study.
CEL-SCI Corp (CVM) Says FDA Requested Changes to Multikine Investigator Brochure
On June 28, 2017 CEL-SCI Corporation received a letter from the U.S. Food and Drug Administration (FDA) in response to CEL-SCI's most recent June 2, 2017 submission regarding the clinical hold imposed on the Company's Phase 3 head and neck cancer study ...
CEL-SCI Corporation Releases Letter to Shareholders
We are giving you an update on clinical hold communications with the U.S. Food and Drug Administration (FDA), the “Agency”, regarding the previously announced partial clinical hold of CEL-SCI's Phase 3 clinical trial of its investigational drug ...
FDA places CEL-SCI's late-stage Multikine study in head and neck cancer ...  Seeking Alpha
CEL-SCI Corporation (CVM) Stock: Takes A Dive On FDA Clinical Hold  CNA Finance (press release)
CEL-SCI Announces Reverse Stock Split
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) announced today that during its annual Shareholder's Meeting on June 12, 2017, a 1-for-25 reverse split was authorized for its outstanding shares of common stock.
CEL-SCI Corporation (AMEX:CVM) Placed in the Hotbed: What Are The Numbers Saying?
After a recent scan, we can see that CEL-SCI Corporation (AMEX:CVM) has a Shareholder Yield of -0.585820 and a Shareholder Yield (Mebane Faber) of -0.58214.
Greenhaven Associates Increased Goldman Sachs (Gs) (GS) Holding; Cel Sci ...  NormanObserver.com
CEL-SCI Co. (CVM) Sees Large Decline in Short Interest  Dispatch Tribunal
CEL-SCI Corp (CVM) Responds to FDA for Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation (NYSE: CVM) today announced that it has responded to the U.S. Food and Drug Administration's (FDA) most recent communication from May 2017 about the clinical hold imposed on the Company's Phase 3 head and neck cancer study with ...
CEL-SCI submits FDA response for its Phase 3 head and neck cancer trial  Seeking Alpha
CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December ...  Business Wire (press release)